Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies

Yuyan Chen, Junko Takita, Mitsuteru Hiwatari, Takashi Igarashi, Ryoji Hanada, Akira Kikuchi, Teruaki Hongo, Tomohiko Taki, Mizuho Ogasawara, Akira Shimada, Yasuhide Hayashi

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

PTPN11 has been identified as a causative gene in Noonan syndrome (NS), responsible for about 50% of cases of NS. Given the association between NS and an increased risk of some malignancies, notably leukemia and probably some solid tumors including neuroblastoma (NB) and rhabdomyosarcoma (RMS), recent studies have reported that gain-of-function somatic mutations in PTPN11 occur in some hematological malignancies, especially de novo juvenile myelomonocytic leukemia (JMML) and in some solid tumors such as NB, although at a low frequency. In a screen for mutations of PTPN11 in 7 cell lines and 30 fresh tumors of RMS and in 25 cell lines and 40 fresh tumors of NB, we identified a missense mutation (A72T) in an embryonal RMS patient. In the RMS samples, we also detected mutations of NRAS in 1 cell line and 1 patient; both mutations were in embryonal RMSs and had no PTPN11 mutations. No mutations of PTPN11 were detected in NB. In 95 leukemia cell lines and 261 fresh leukemia samples including 22 JMMLs, 9 kinds of missense mutations were detected in 17 leukemia samples, which included 11 (50.0%) mutations in JMML samples and lower frequencies in other hematological malignancies. Furthermore, we identified 4 (18.2%) NRAS mutations and 1 (4.5%) KRAS mutation in 5 JMML samples, 1 of which had a concomitant PTPN11 mutation. Our data suggest that mutations of PTPN11 as well as RAS play a role in the pathogenesis of not only myeloid hematological malignancies but also a subset of RMS malignancies.

Original languageEnglish
Pages (from-to)583-591
Number of pages9
JournalGenes Chromosomes and Cancer
Volume45
Issue number6
DOIs
Publication statusPublished - Jun 2006
Externally publishedYes

Fingerprint

Rhabdomyosarcoma
Hematologic Neoplasms
Pediatrics
Mutation
Genes
Juvenile Myelomonocytic Leukemia
Noonan Syndrome
Neuroblastoma
Leukemia
Cell Line
Neoplasms
Missense Mutation
Embryonal Rhabdomyosarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Chen, Y., Takita, J., Hiwatari, M., Igarashi, T., Hanada, R., Kikuchi, A., ... Hayashi, Y. (2006). Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes and Cancer, 45(6), 583-591. https://doi.org/10.1007/s11103-005-5082-x

Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. / Chen, Yuyan; Takita, Junko; Hiwatari, Mitsuteru; Igarashi, Takashi; Hanada, Ryoji; Kikuchi, Akira; Hongo, Teruaki; Taki, Tomohiko; Ogasawara, Mizuho; Shimada, Akira; Hayashi, Yasuhide.

In: Genes Chromosomes and Cancer, Vol. 45, No. 6, 06.2006, p. 583-591.

Research output: Contribution to journalArticle

Chen, Y, Takita, J, Hiwatari, M, Igarashi, T, Hanada, R, Kikuchi, A, Hongo, T, Taki, T, Ogasawara, M, Shimada, A & Hayashi, Y 2006, 'Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies', Genes Chromosomes and Cancer, vol. 45, no. 6, pp. 583-591. https://doi.org/10.1007/s11103-005-5082-x
Chen, Yuyan ; Takita, Junko ; Hiwatari, Mitsuteru ; Igarashi, Takashi ; Hanada, Ryoji ; Kikuchi, Akira ; Hongo, Teruaki ; Taki, Tomohiko ; Ogasawara, Mizuho ; Shimada, Akira ; Hayashi, Yasuhide. / Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. In: Genes Chromosomes and Cancer. 2006 ; Vol. 45, No. 6. pp. 583-591.
@article{16fd8286129b4043a50a69df8b059799,
title = "Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies",
abstract = "PTPN11 has been identified as a causative gene in Noonan syndrome (NS), responsible for about 50{\%} of cases of NS. Given the association between NS and an increased risk of some malignancies, notably leukemia and probably some solid tumors including neuroblastoma (NB) and rhabdomyosarcoma (RMS), recent studies have reported that gain-of-function somatic mutations in PTPN11 occur in some hematological malignancies, especially de novo juvenile myelomonocytic leukemia (JMML) and in some solid tumors such as NB, although at a low frequency. In a screen for mutations of PTPN11 in 7 cell lines and 30 fresh tumors of RMS and in 25 cell lines and 40 fresh tumors of NB, we identified a missense mutation (A72T) in an embryonal RMS patient. In the RMS samples, we also detected mutations of NRAS in 1 cell line and 1 patient; both mutations were in embryonal RMSs and had no PTPN11 mutations. No mutations of PTPN11 were detected in NB. In 95 leukemia cell lines and 261 fresh leukemia samples including 22 JMMLs, 9 kinds of missense mutations were detected in 17 leukemia samples, which included 11 (50.0{\%}) mutations in JMML samples and lower frequencies in other hematological malignancies. Furthermore, we identified 4 (18.2{\%}) NRAS mutations and 1 (4.5{\%}) KRAS mutation in 5 JMML samples, 1 of which had a concomitant PTPN11 mutation. Our data suggest that mutations of PTPN11 as well as RAS play a role in the pathogenesis of not only myeloid hematological malignancies but also a subset of RMS malignancies.",
author = "Yuyan Chen and Junko Takita and Mitsuteru Hiwatari and Takashi Igarashi and Ryoji Hanada and Akira Kikuchi and Teruaki Hongo and Tomohiko Taki and Mizuho Ogasawara and Akira Shimada and Yasuhide Hayashi",
year = "2006",
month = "6",
doi = "10.1007/s11103-005-5082-x",
language = "English",
volume = "45",
pages = "583--591",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies

AU - Chen, Yuyan

AU - Takita, Junko

AU - Hiwatari, Mitsuteru

AU - Igarashi, Takashi

AU - Hanada, Ryoji

AU - Kikuchi, Akira

AU - Hongo, Teruaki

AU - Taki, Tomohiko

AU - Ogasawara, Mizuho

AU - Shimada, Akira

AU - Hayashi, Yasuhide

PY - 2006/6

Y1 - 2006/6

N2 - PTPN11 has been identified as a causative gene in Noonan syndrome (NS), responsible for about 50% of cases of NS. Given the association between NS and an increased risk of some malignancies, notably leukemia and probably some solid tumors including neuroblastoma (NB) and rhabdomyosarcoma (RMS), recent studies have reported that gain-of-function somatic mutations in PTPN11 occur in some hematological malignancies, especially de novo juvenile myelomonocytic leukemia (JMML) and in some solid tumors such as NB, although at a low frequency. In a screen for mutations of PTPN11 in 7 cell lines and 30 fresh tumors of RMS and in 25 cell lines and 40 fresh tumors of NB, we identified a missense mutation (A72T) in an embryonal RMS patient. In the RMS samples, we also detected mutations of NRAS in 1 cell line and 1 patient; both mutations were in embryonal RMSs and had no PTPN11 mutations. No mutations of PTPN11 were detected in NB. In 95 leukemia cell lines and 261 fresh leukemia samples including 22 JMMLs, 9 kinds of missense mutations were detected in 17 leukemia samples, which included 11 (50.0%) mutations in JMML samples and lower frequencies in other hematological malignancies. Furthermore, we identified 4 (18.2%) NRAS mutations and 1 (4.5%) KRAS mutation in 5 JMML samples, 1 of which had a concomitant PTPN11 mutation. Our data suggest that mutations of PTPN11 as well as RAS play a role in the pathogenesis of not only myeloid hematological malignancies but also a subset of RMS malignancies.

AB - PTPN11 has been identified as a causative gene in Noonan syndrome (NS), responsible for about 50% of cases of NS. Given the association between NS and an increased risk of some malignancies, notably leukemia and probably some solid tumors including neuroblastoma (NB) and rhabdomyosarcoma (RMS), recent studies have reported that gain-of-function somatic mutations in PTPN11 occur in some hematological malignancies, especially de novo juvenile myelomonocytic leukemia (JMML) and in some solid tumors such as NB, although at a low frequency. In a screen for mutations of PTPN11 in 7 cell lines and 30 fresh tumors of RMS and in 25 cell lines and 40 fresh tumors of NB, we identified a missense mutation (A72T) in an embryonal RMS patient. In the RMS samples, we also detected mutations of NRAS in 1 cell line and 1 patient; both mutations were in embryonal RMSs and had no PTPN11 mutations. No mutations of PTPN11 were detected in NB. In 95 leukemia cell lines and 261 fresh leukemia samples including 22 JMMLs, 9 kinds of missense mutations were detected in 17 leukemia samples, which included 11 (50.0%) mutations in JMML samples and lower frequencies in other hematological malignancies. Furthermore, we identified 4 (18.2%) NRAS mutations and 1 (4.5%) KRAS mutation in 5 JMML samples, 1 of which had a concomitant PTPN11 mutation. Our data suggest that mutations of PTPN11 as well as RAS play a role in the pathogenesis of not only myeloid hematological malignancies but also a subset of RMS malignancies.

UR - http://www.scopus.com/inward/record.url?scp=33646589708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646589708&partnerID=8YFLogxK

U2 - 10.1007/s11103-005-5082-x

DO - 10.1007/s11103-005-5082-x

M3 - Article

VL - 45

SP - 583

EP - 591

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 6

ER -